Hetai Biomedical Capital

The firm targets both early-stage seed rounds and later-stage buyouts, according to its own business description. This combines venture-level scientific risk with private equity operational control mandates, primarily in medical devices and diagnostics.

Xi'an hosts the Fourth Military Medical University, Xi'an Jiaotong University's biomedical engineering program, and a growing base of medical-device manufacturers serving western and central Chinese hospitals. The city is part of a second-wave innovation corridor beyond Shanghai/Suzhou/Shenzhen, offering access to deal flow that coastal funds often do not cultivate.

No. The firm does not publicly report AUM, and it does not appear in major regulatory filings or international private equity databases. This is common for Chinese emerging managers that raise capital from domestic high-net-worth individuals and corporate partners rather than institutional limited partners subject to disclosure requirements.

The firm's named focus on biomedical and healthcare suggests it does not invest in consumer internet, enterprise software, clean energy, or other generalist venture themes. Its mandate appears concentrated entirely within medical devices, diagnostics, and digital health.

The firm's Xi'an base gives it proximity to university-hospital networks, contract research organizations, and provincial device manufacturers. While no specific sourcing channels are publicly disclosed, second-tier-city funds in China typically rely on local university tech-transfer offices, hospital-purchasing relationships, and provincial government biomedical parks rather than competitive auction processes.